{"id":727613,"date":"2023-02-01T08:17:01","date_gmt":"2023-02-01T13:17:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/"},"modified":"2023-02-01T08:17:01","modified_gmt":"2023-02-01T13:17:01","slug":"merus-to-participate-in-upcoming-investor-conferences-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/","title":{"rendered":"Merus to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb.  01, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8fkiy9t7MyyKkW3u74GQm_K6Vlio9dtZ-AqobGLdLvGU-Q4_w4uiX6pfk27qeJTe\" rel=\"nofollow noopener\" target=\"_blank\">Merus N.V<\/a>. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics<sup>\u00ae<\/sup> and Triclonics<sup>\u00ae<\/sup>), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Guggenheim Healthcare Talks\/Oncology Conference: Wednesday, February 8 at 11:20-11:45 a.m. ET<\/li>\n<li style=\"margin-bottom:8pt\">SVB Securities Global Biopharma Conference: Tuesday, February 14 at 3:40-4:10 p.m. ET<\/li>\n<li style=\"margin-bottom:8pt\">Citi&#8217;s 2023 Oncology Leadership Summit: Thursday, February 23 at 10:00-11:00 a.m. ET<\/li>\n<\/ul>\n<p>The webcasts of the presentations will be contemporaneously available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iuzYEt1igHCTOoIez9GiTxN2jEwI9aHLAoo5h4nhry-hUSAtQcx4QaYxumoZLecGG4tDJ-N5CAiK8i0FOtN7ItfRna1gykiBQGa5XcS9hsQ=\" rel=\"nofollow noopener\" target=\"_blank\">Investors page<\/a> of the Company&#8217;s website. Archived presentations will also be available there for a limited time after the event.<\/p>\n<p>\n        <strong><br \/>\n          <strong>About Merus<\/strong><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f6dPzLGeUpIP8sNnqsAgn50qmoul_Fu6ArICDRMzXdQNSo_aCqpUXx2ZRHnxhYyjZgKWbYrF9v65ERaQGCy6Lw==\" rel=\"nofollow noopener\" target=\"_blank\">Merus<\/a> is a clinical-stage oncology company developing innovative full-length human bispecific and\u00a0trispecific antibody therapeutics, referred to as <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Wy5ZN0-JmafUZimLjxDEm9BLu-lkZZzrcaRXnMXB2pV-DMVGuKF_THOeIa6Clda6QE0pp4OHSHHw-QxQH4SH2LLRnwkqSxGICxfhNz6w5F0xJEHnL_0-84GvPKPB-NBI\" rel=\"nofollow noopener\" target=\"_blank\">Multiclonics<sup>\u00ae<\/sup><\/a>. Multiclonics<sup>\u00ae<\/sup> are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of\u00a0the same features of conventional human monoclonal antibodies, such as long half-life and low\u00a0immunogenicity. For additional information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W2dcBGvP-R0Jdx1BihiuK0vuRKMxJKL-hlPuEXdSrDGBOX6Ygkz3fDhNOWrU8d32VGmhyXnxJnYabic3fUa1Bg==\" rel=\"nofollow noopener\" target=\"_blank\">Merus\u2019 website<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gJ7v3lmgFpnrXjXsv0M_UGn77sfL-Lou4fabETuRiQNYKv7wjNRRrGdKNApm447ScljACB-kzp_cOKyXr7H3mA==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p>Multiclonics<sup>\u00ae<\/sup>, Biclonics<sup>\u00ae<\/sup>\u00a0and Triclonics<sup>\u00ae<\/sup>\u00a0are registered trademarks of Merus N.V.\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDEwMyM1Mzg0MjYxIzIwMjAyODc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MWM4NzBiMmUtNDUxYy00NThmLWJjN2ItYzljYjVmZDQyZDY2LTEwMzE4NTk=\/tiny\/Merus-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor and Media Inquiries:\r\nSherri Spear\r\nMerus N.V.\r\nVP Investor Relations and Corporate Communications\r\n617-821-3246\r\ns.spear@merus.nl\r\n\r\nKathleen Farren\r\nMerus N.V.\r\nIR\/Corp Comms\r\n617-230-4165\r\nk.farren@merus.nl<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics\u00ae and Triclonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences: Guggenheim Healthcare Talks\/Oncology Conference: Wednesday, February 8 at 11:20-11:45 a.m. ET SVB Securities Global Biopharma Conference: Tuesday, February 14 at 3:40-4:10 p.m. ET Citi&#8217;s 2023 Oncology Leadership Summit: Thursday, February 23 at 10:00-11:00 a.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company&#8217;s website. Archived presentations will also be available there for a limited time after the event. About Merus Merus &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Merus to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-727613","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merus to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merus to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics\u00ae and Triclonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences: Guggenheim Healthcare Talks\/Oncology Conference: Wednesday, February 8 at 11:20-11:45 a.m. ET SVB Securities Global Biopharma Conference: Tuesday, February 14 at 3:40-4:10 p.m. ET Citi&#8217;s 2023 Oncology Leadership Summit: Thursday, February 23 at 10:00-11:00 a.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company&#8217;s website. Archived presentations will also be available there for a limited time after the event. About Merus Merus &hellip; Continue reading &quot;Merus to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T13:17:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDEwMyM1Mzg0MjYxIzIwMjAyODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Merus to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2023-02-01T13:17:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/\"},\"wordCount\":200,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDEwMyM1Mzg0MjYxIzIwMjAyODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/\",\"name\":\"Merus to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDEwMyM1Mzg0MjYxIzIwMjAyODc=\",\"datePublished\":\"2023-02-01T13:17:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDEwMyM1Mzg0MjYxIzIwMjAyODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDEwMyM1Mzg0MjYxIzIwMjAyODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-participate-in-upcoming-investor-conferences-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merus to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merus to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/","og_locale":"en_US","og_type":"article","og_title":"Merus to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics\u00ae and Triclonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences: Guggenheim Healthcare Talks\/Oncology Conference: Wednesday, February 8 at 11:20-11:45 a.m. ET SVB Securities Global Biopharma Conference: Tuesday, February 14 at 3:40-4:10 p.m. ET Citi&#8217;s 2023 Oncology Leadership Summit: Thursday, February 23 at 10:00-11:00 a.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company&#8217;s website. Archived presentations will also be available there for a limited time after the event. About Merus Merus &hellip; Continue reading \"Merus to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-01T13:17:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDEwMyM1Mzg0MjYxIzIwMjAyODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Merus to Participate in Upcoming Investor Conferences","datePublished":"2023-02-01T13:17:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/"},"wordCount":200,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDEwMyM1Mzg0MjYxIzIwMjAyODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/","name":"Merus to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDEwMyM1Mzg0MjYxIzIwMjAyODc=","datePublished":"2023-02-01T13:17:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDEwMyM1Mzg0MjYxIzIwMjAyODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDEwMyM1Mzg0MjYxIzIwMjAyODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-participate-in-upcoming-investor-conferences-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Merus to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=727613"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727613\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=727613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=727613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=727613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}